Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure — Inês Pires da Silva (2025) | RDL Network
Evidence supporting the efficacy of subsequent ICI treatment is strongest in melanoma, but the level of evidence remains low overall. Prospective studies and improved reporting of subsequent ICI therapy in existing trials investigating long-term outcomes, standardized predictive factors, and treatment modalities are warranted.
Judith M. Versluis, Anne M. Hendriks, Alison M. Weppler, Lauren Brown, Karlijn de Joode, Karijn P.M. Suijkerbuijk, Lisa Zimmer, Ellen Kapiteijn, Clara Allayous, Douglas B. Johnson, Adriana Hepner, Joanna Mangana, Prachi Bhave, Yanina Jansen, Claudia Trojaniello, Victoria Atkinson, Lucy Storey, Paul Lorigan, Paolo A. Ascierto, Bart Neyns, Andrew Haydon, Alexander M. Menzies, Georgina V. Long,
Anna Galligan, Roslyn Wallace, Balasubramanian Krishnamurthy, Thomas W. H. Kay, Nirupa Sachithanandan, Cherie Chiang, Shahneen Sandhu, Rodney J. Hicks, Amir Iravani
Linda Wu, John M. Wentworth, Christopher Liddle, Nicole Fewings, Matteo S. Carlino, David A. Brown, Roderick Clifton‐Bligh, Georgina V. Long, Richard A Scolyer, Nicholas Norris, Sarah C. Sasson, Venessa Tsang, Alexander M. Menzies, Jenny E. Gunton
Discussion(0)
No comments yet. Be the first to comment.